{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:16:20Z","timestamp":1791278180796,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:sup>18<\/jats:sup>F-fluoromisonidazole (FMISO) has been widely used as a hypoxia imaging probe for diagnostic positron emission tomography (PET). FMISO is believed to accumulate in hypoxic cells via covalent binding with macromolecules after reduction of its nitro group. However, its detailed accumulation mechanism remains unknown. Therefore, we investigated the chemical forms of FMISO and their distributions in tumours using imaging mass spectrometry (IMS), which visualises spatial distribution of chemical compositions based on molecular masses in tissue sections. Our radiochemical analysis revealed that most of the radioactivity in tumours existed as low-molecular-weight compounds with unknown chemical formulas, unlike observations made with conventional views, suggesting that the radioactivity distribution primarily reflected that of these unknown substances. The IMS analysis indicated that FMISO and its reductive metabolites were nonspecifically distributed in the tumour in patterns not corresponding to the radioactivity distribution. Our IMS search found an unknown low-molecular-weight metabolite whose distribution pattern corresponded to that of both the radioactivity and the hypoxia marker pimonidazole. This metabolite was identified as the glutathione conjugate of amino-FMISO. We showed that the glutathione conjugate of amino-FMISO is involved in FMISO accumulation in hypoxic tumour tissues, in addition to the conventional mechanism of FMISO covalent binding to macromolecules.<\/jats:p>","DOI":"10.1038\/srep16802","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T10:04:52Z","timestamp":1447927492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["The accumulation mechanism of the hypoxia imaging probe \u201cFMISO\u201d by imaging mass spectrometry: possible involvement of low-molecular metabolites"],"prefix":"10.1038","volume":"5","author":[{"given":"Yukiko","family":"Masaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songji","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Higashino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagara","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,19]]},"reference":[{"key":"BFsrep16802_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer. 11, 393\u2013410 (2011).","journal-title":"Nat. Rev. Cancer."},{"key":"BFsrep16802_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2012.171","volume":"9","author":"MR Horsman","year":"2012","unstructured":"Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M. & Overgaard, J. Imaging hypoxia to improve radiotherapy outcome. Nat. Rev. Clin. Oncol. 9, 674\u2013687 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFsrep16802_CR3","doi-asserted-by":"publisher","first-page":"129S","DOI":"10.2967\/jnumed.107.045914","volume":"49","author":"KA Krohn","year":"2008","unstructured":"Krohn, K. A., Link, J. M. & Mason, R. P. Molecular imaging of hypoxia. J. Nucl. Med. 49 Suppl 2, 129S\u2013148S (2008).","journal-title":"J. Nucl. Med."},{"key":"BFsrep16802_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/nature06917","volume":"452","author":"R Weissleder","year":"2008","unstructured":"Weissleder, R. & Pittet, M. J. Imaging in the era of molecular oncology. Nature. 452, 580\u2013589 (2008).","journal-title":"Nature."},{"key":"BFsrep16802_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF01081524","volume":"22","author":"A Nunn","year":"1995","unstructured":"Nunn, A., Linder, K. & Strauss, H. W. Nitroimidazoles and imaging hypoxia. Eur. J. Nucl. Med. 22, 265\u2013280 (1995).","journal-title":"Eur. J. Nucl. Med."},{"key":"BFsrep16802_CR6","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00259-008-0772-7","volume":"35","author":"EG Troost","year":"2008","unstructured":"Troost, E. G. et al. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. Eur. J. Nucl. Med. Mol. Imaging. 35, 1803\u20131811 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"BFsrep16802_CR7","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1021\/ac970888i","volume":"69","author":"RM Caprioli","year":"1997","unstructured":"Caprioli, R. M., Farmer, T. B. & Gile, J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal. Chem. 69, 4751\u20134760 (1997).","journal-title":"Anal. Chem."},{"key":"BFsrep16802_CR8","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1021\/ac0506130","volume":"77","author":"J Gobey","year":"2005","unstructured":"Gobey, J. et al. Characterization and performance of MALDI on a triple quadrupole mass spectrometer for analysis and quantification of small molecules. Anal. Chem. 77, 5643\u20135654 (2005).","journal-title":"Anal. Chem."},{"key":"BFsrep16802_CR9","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1021\/ac00117a025","volume":"67","author":"JA Marto","year":"1995","unstructured":"Marto, J. A., White, F. M., Seldomridge, S. & Marshall, A. G. Structural characterization of phospholipids by matrix-assisted laser desorption\/ionization Fourier transform ion cyclotron resonance mass spectrometry. Anal. Chem. 67, 3979\u20133984 (1995).","journal-title":"Anal. Chem."},{"key":"BFsrep16802_CR10","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/rcm.2434","volume":"20","author":"S Vaidyanathan","year":"2006","unstructured":"Vaidyanathan, S., Gaskell, S. & Goodacre, R. Matrix-suppressed laser desorption\/ionisation mass spectrometry and its suitability for metabolome analyses. Rapid. Commun. Mass. Spectrom. 20, 1192\u20131198 (2006).","journal-title":"Rapid. Commun. Mass. Spectrom."},{"key":"BFsrep16802_CR11","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.4155\/bio.11.232","volume":"3","author":"S Castellino","year":"2011","unstructured":"Castellino, S., Groseclose, M. R. & Wagner, D. MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. Bioanalysis. 3, 2427\u20132441 (2011).","journal-title":"Bioanalysis."},{"key":"BFsrep16802_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.aca.2013.06.022","volume":"788","author":"C Xie","year":"2013","unstructured":"Xie, C., Zhong, D. & Chen, X. A fragmentation-based method for the differentiation of glutathione conjugates by high-resolution mass spectrometry with electrospray ionization. Anal. Chim. Acta. 788, 89\u201398 (2013).","journal-title":"Anal. Chim. Acta."},{"key":"BFsrep16802_CR13","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/0006-2952(91)90245-Z","volume":"42","author":"JL Prekeges","year":"1991","unstructured":"Prekeges, J. L., Rasey, J. S., Grunbaum, Z. & Krohn, K. H. Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem. Pharmacol. 42, 2387\u20132395 (1991).","journal-title":"Biochem. Pharmacol."},{"key":"BFsrep16802_CR14","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.1021\/ja00203a018","volume":"111","author":"JL Bolton","year":"1989","unstructured":"Bolton, J. L. & McClelland, R. A. Kinetics and mechanism of the decomposition in aqueous solutions of 2-(hydroxyamino)imidazoles. J. Am. Chem. Soc. 111, 8172\u20138181 (1989).","journal-title":"J. Am. Chem. Soc."},{"key":"BFsrep16802_CR15","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/0006-2952(90)90086-Z","volume":"40","author":"JA Raleigh","year":"1990","unstructured":"Raleigh, J. A. & Koch, C. J. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem. Pharmacol. 40, 2457\u20132464 (1990).","journal-title":"Biochem. Pharmacol."},{"key":"BFsrep16802_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cbi.2008.09.014","volume":"179","author":"S Ma","year":"2009","unstructured":"Ma, S. & Zhu, M. Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. Chem. Biol. Interact. 179, 25\u201337 (2009).","journal-title":"Chem. Biol. Interact."},{"key":"BFsrep16802_CR17","doi-asserted-by":"crossref","unstructured":"Mclelland, R. A. Molecular interactions and biological effects of the products of reduction of nitroimidazoles. NATO Advanced Research Workshop on Selective Activation of Drugs by Redox Processes (eds Adams, G.E. et al. ) 125\u2013136 (Plenum Press, 1990).","DOI":"10.1007\/978-1-4615-3768-7_11"},{"key":"BFsrep16802_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0009-2797(81)90016-8","volume":"36","author":"AJ Varghese","year":"1981","unstructured":"Varghese, A. J. & Whitmore, G. F. Cellular and chemical reduction products of misonidazole. Chem. Biol. Interact. 36, 141\u2013151 (1981).","journal-title":"Chem. Biol. Interact."},{"key":"BFsrep16802_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2307\/3577760","volume":"122","author":"JS Rasey","year":"1990","unstructured":"Rasey, J. S., Nelson, N. J., Chin, L., Evans, M. L. & Grunbaum, Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat. Res. 122, 301\u2013308 (1990).","journal-title":"Radiat. Res."},{"key":"BFsrep16802_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.vascn.2006.06.004","volume":"55","author":"Y Hsieh","year":"2007","unstructured":"Hsieh, Y., Chen, J. & Korfmacher, W. A. Mapping pharmaceuticals in tissues using MALDI imaging mass spectrometry. J. Pharmacol. Toxicol. Methods. 55, 193\u2013200 (2007).","journal-title":"J. Pharmacol. Toxicol. Methods."},{"key":"BFsrep16802_CR21","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1021\/ac902931x","volume":"82","author":"D Miura","year":"2010","unstructured":"Miura, D., Tsuji, Y., Takahashi, K., Wariishi, H. & Saito, K. A strategy for the determination of the elemental composition by Fourier transform ion cyclotron resonance mass spectrometry based on isotopic peak ratios. Anal. Chem. 82, 5887\u20135891 (2010).","journal-title":"Anal. Chem."},{"key":"BFsrep16802_CR22","doi-asserted-by":"publisher","first-page":"5648","DOI":"10.1021\/ac800617s","volume":"80","author":"DS Cornett","year":"2008","unstructured":"Cornett, D. S., Frappier, S. L. & Caprioli, R. M. MALDI-FTICR imaging mass spectrometry of drugs and metabolites in tissue. Anal. Chem. 80, 5648\u20135653 (2008).","journal-title":"Anal. Chem."},{"key":"BFsrep16802_CR23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0360-3016(96)00539-1","volume":"37","author":"AS Kennedy","year":"1997","unstructured":"Kennedy, A. S. et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int. J. Radiat. Oncol. Biol. Phys. 37, 897\u2013905 (1997).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFsrep16802_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.nucmedbio.2005.03.010","volume":"32","author":"G Tang","year":"2005","unstructured":"Tang, G., Wang, M., Tang, X., Gan, M. & Luo, L. Fully automated one-pot synthesis of [18F]fluoromisonidazole. Nucl. Med. Biol. 32, 553\u2013558 (2005).","journal-title":"Nucl. Med. Biol."},{"key":"BFsrep16802_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12149-013-0693-9","volume":"27","author":"CN Fatema","year":"2013","unstructured":"Fatema, C. N. et al. Monitoring tumor proliferative response to radiotherapy using (18)F-fluorothymidine in human head and neck cancer xenograft in comparison with Ki-67. Ann. Nucl. Med. 27, 355\u2013362 (2013).","journal-title":"Ann. Nucl. Med."},{"key":"BFsrep16802_CR26","first-page":"1854","volume":"36","author":"RS Brown","year":"1995","unstructured":"Brown, R. S. et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J. Nucl. Med. 36, 1854\u20131861 (1995).","journal-title":"J. Nucl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep16802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep16802","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep16802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T19:01:30Z","timestamp":1672945290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep16802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,22]]}},"alternative-id":["BFsrep16802"],"URL":"https:\/\/doi.org\/10.1038\/srep16802","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]},"assertion":[{"value":"21 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof. Yuji Kuge has grant support from Shionogi & Co., Ltd. The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16802"}}